Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

PURPOSE: Enhanced MAPK pathway signaling and cell-cycle checkpoint dysregulation are frequent in NRAS-mutant melanoma and, as such, the regimen of the MEK inhibitor binimetinib and the selective CDK4/6 inhibitor ribociclib is a rational combination. PATIENTS AND METHODS: This is a phase Ib/II, open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuler, Martin, Zimmer, Lisa, Kim, Kevin B., Sosman, Jeffrey A., Ascierto, Paolo A., Postow, Michael A., De Vos, Filip Y.F.L., van Herpen, Carla M.L., Carlino, Matteo S., Johnson, Douglas B., Berking, Carola, Reddy, Micaela B., Harney, Allison S., Berlin, Jordan D., Amaria, Rodabe N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365377/
https://www.ncbi.nlm.nih.gov/pubmed/35294522
http://dx.doi.org/10.1158/1078-0432.CCR-21-3872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365377/
https://www.ncbi.nlm.nih.gov/pubmed/35294522
http://dx.doi.org/10.1158/1078-0432.CCR-21-3872

Ejemplares similares